Vanguard Group Inc. lifted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report) by 0.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,199,006 shares of the company’s stock after acquiring an additional 11,535 shares during the quarter. Vanguard Group Inc.’s holdings in Terns Pharmaceuticals were worth $14,425,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of TERN. Bleakley Financial Group LLC acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $68,000. Simplicity Solutions LLC acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $68,000. Russell Investments Group Ltd. acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $1,803,000. AJOVista LLC acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $58,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $106,000. Institutional investors and hedge funds own 98.26% of the company’s stock.
Insider Transactions at Terns Pharmaceuticals
In other news, Director Jill M. Quigley sold 6,143 shares of Terns Pharmaceuticals stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $7.68, for a total value of $47,178.24. Following the completion of the transaction, the director now directly owns 23,857 shares of the company’s stock, valued at approximately $183,221.76. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Carl L. Gordon sold 50,976 shares of Terns Pharmaceuticals stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $10.00, for a total value of $509,760.00. Following the completion of the transaction, the director now directly owns 756,258 shares of the company’s stock, valued at approximately $7,562,580. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jill M. Quigley sold 6,143 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $7.68, for a total value of $47,178.24. Following the completion of the sale, the director now directly owns 23,857 shares of the company’s stock, valued at $183,221.76. The disclosure for this sale can be found here. Corporate insiders own 15.10% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Analysis on Terns Pharmaceuticals
Terns Pharmaceuticals Stock Down 0.2 %
Shares of NASDAQ:TERN opened at $6.57 on Tuesday. Terns Pharmaceuticals, Inc. has a 12-month low of $3.26 and a 12-month high of $10.03. The business has a fifty day simple moving average of $7.64 and a 200 day simple moving average of $6.70.
Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) last announced its earnings results on Monday, August 5th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.04. On average, analysts forecast that Terns Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.
Terns Pharmaceuticals Company Profile
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Further Reading
- Five stocks we like better than Terns Pharmaceuticals
- How to Use the MarketBeat Stock Screener
- How to Invest in Silver: A Beginner’s Guide
- The 3 Best Retail Stocks to Shop for in August
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Want to see what other hedge funds are holding TERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report).
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.